<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>(2E)-2-{6-[(E)-2-carboxylvinyl]-2,3-dihydroxyphenyl}-3-(3,4-dihydroxyphenyl) <z:chebi fb="0" ids="18308">propenoic acid</z:chebi>, a novel compound designated SMND-309, is a new degradation product of salvianolic acid B </plain></SENT>
<SENT sid="1" pm="."><plain>The present study was conducted to evaluate whether SMND-309 has a protective effect on permanent focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in rats </plain></SENT>
<SENT sid="2" pm="."><plain>The results showed that SMND-309 at doses higher than 4.0 mg/kg (i.v.) produced a significant neuroprotection in focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> rats when administered 30 min after the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>SMND-309 (25.0 mg/kg, i.v.) demonstrated significant neuroprotective activity even after delayed administration at 1 h, 3 h and 6 h after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>The neuroprotective effect of SMND-309 (25.0 mg/kg, bolus injection intravenous at 30 min after middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp>) was still present 7 days after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Meanwhile, SMND-309 significantly increased the brain ATP content, improved <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> energy metabolism and <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> respiratory chain complex activities and attenuated the elevation of malondialdehyde (<z:chebi fb="14" ids="32506">MDA</z:chebi>) content, the decrease in <z:chebi fb="1" ids="18421">superoxide</z:chebi> dismutase (SOD) and <z:chebi fb="0" ids="16856">glutathione</z:chebi>-peroxidase (GSH-Px) activity in brain mitochondria </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> of these findings indicate that SMND-309 exerts potent and long-term neuroprotective effects with a favorable therapeutic time-window in the model of permanent <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, and its protective effects may be due to the amelioration of cerebral <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> energy metabolism and the <z:chebi fb="11" ids="22586">antioxidant</z:chebi> property </plain></SENT>
</text></document>